首页|抗体偶联药物诱导的间质性肺病的发病机制

抗体偶联药物诱导的间质性肺病的发病机制

扫码查看
原文链接
  • 万方数据
  • 维普
药物性间质性肺病(drug-induced interstitial lung disease,DI-ILD)是药物所致肺部不良事件的最常见形式,其最常见原因是抗癌药物.DI-ILD首次被确定为一种需要特别关注的不良事件是因抗体偶联药物(antibody-drug conjugates,ADC).随着研发药物数量和种类的增多、多款ADC药物被批准或即将被批准用于临床治疗,DI-ILD引发了越来越多的关注.然而,ADC药物引发DI-ILD的机制尚未明确,本文就目前常见且应用广泛的抗人表皮生长因子受体 2(human epidermal growth factor receptor 2,HER2)ADC药物DI-ILD的发生机制进行综述.
Pathogenesis of antibody-drug conjugates-induced interstitial lung disease
Drug-induced interstitial lung disease(DI-ILD)is the most common form of drug-induced pulmonary adverse events,with antican-cer drugs being the primary cause.DI-ILD first gained attention as a notable adverse event due to the use of antibody-drug conjugates(ADC).As the development of drugs,particularly ADCs,continues to expand and more ADCs are approved or nearing approved for clinical use,DI-ILD has become an area of growing concern.However,the mechanisms by which ADCs induce ILD remain unclear.This article reviews the mechanisms of DI-ILD in the most commonly used ADCs targeting human epidermal growth factor receptor 2(HER2).

drug-induced interstitial lung disease(DI-ILD)interstitial lung diseaseanticancer drugsantibody-drug conjugates(ADCs)human epidermal growth factor receptor 2(HER2)

赵翠翠、张传桂

展开 >

天津医科大学肿瘤医院特需病房,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室(天津市 300060)

药物性间质性肺病 间质性肺病 抗癌药物 抗体偶联药物 人表皮生长因子受体2

国家自然科学基金项目国家自然科学基金项目天津市医学重点学科(专科)建设项目天津医科大学肿瘤医院国家自然科学基金培育项目

8237211082403936TJYXZDXK-009A230104

2024

10.12354/j.issn.1000-8179.2024.20240908

中国肿瘤临床
中国抗癌协会

中国肿瘤临床

CSTPCD北大核心
影响因子：1.32
ISSN：1000-8179
年,卷(期)：2024.51(15)
  • 1